News
A Bristol-headquartered company that has developed technology to help disabled people who experience difficulty with speech ...
Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results